A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Condition(s):Thymic CarcinomaLast Updated:August 25, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Thymic CarcinomaLast Updated:August 25, 2023Terminated
Condition(s):Thymic CarcinomaLast Updated:March 12, 2024Terminated
Condition(s):Thymoma and Thymic CarcinomaLast Updated:September 10, 2022Completed
Condition(s):Untreated Advanced or Recurrent Thymic CarcinomasLast Updated:October 23, 2023Recruiting
Condition(s):Thymic CarcinomaLast Updated:January 23, 2019Completed
Condition(s):Thymoma and Thymic CarcinomaLast Updated:December 5, 2023Recruiting
Condition(s):Metastatic Thymic Carcinoma; Thymoma Type B3Last Updated:March 22, 2024Active, not recruiting
Condition(s):Thymoma; Thymic Carcinoma; Thymic Carcinoid; Thymic Neuroendocrine TumorsLast Updated:December 23, 2016Completed
Condition(s):Thymoma; Thymic Carcinoma; Clinical Masaoka Stage II to IVALast Updated:May 31, 2023Active, not recruiting
Condition(s):Thymoma Type B3; Thymic CarcinomaLast Updated:February 21, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.